The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis A virus seroprevalence

G. S. A. Smit, S. Abrams, P. Dorny, N. Speybroeck, B. Devleesschauwer, V Hutse, H. Jansens, H. Theeten, P. Beutels, N. Hens

Research output: Contribution to journalA1: Web of Science-article

Abstract

Cytomegalovirus (CMV) infection is endemic worldwide but its seroprevalence varies widely. The goal of this study was to estimate the age-specific seroprevalence of CMV infection in Belgium based on two cross-sectional serological datasets from 2002 and 2006. The seroprevalence was estimated relying on diagnostic test results based on cut-off values pre-specified by the manufacturers of the tests as well as relying on mixture models applied to continuous pathogen-specific immunoglobulin G antibody titre concentrations. The age-specific seroprevalence of hepatitis A virus (HAV), based on three Belgian cross-sectional serological datasets from 1993, 2002 and 2006, was used as a comparator since individuals acquire lifelong immunity upon recovery, implying an increasing seroprevalence with age. The age group weighted overall CMV seroprevalence derived from the mixture model was 32% (95% confidence interval (CI) 31-34%) in 2002 and 31% (95% CI 30-32%) in 2006. We demonstrated that CMV epidemiology differs from the immunizing infection HAV. This was the first large-scale study of CMV and HAV serial datasets in Belgium, estimating seroprevalence specified by age and birth cohort.

Original languageEnglish
Article number154
JournalEpidemiology and Infection
Volume147
Pages (from-to)e154
Number of pages9
ISSN0950-2688
DOIs
Publication statusPublished - 2019

Keywords

  • Cytomegalovirus
  • hepatitis A virus
  • estimating age and birth cohort-specific seroprevalence
  • seroincidence
  • mixture modelling
  • WANING IMMUNITY
  • MIXTURE-MODELS
  • SEROEPIDEMIOLOGY
  • ANTIBODY
  • RUBELLA
  • PREVALENCE
  • VACCINATION
  • PERTUSSIS
  • EPIDEMIC
  • ENGLAND

Cite this